Objectives
To examine the relationship between fibroblast growth factor‐23 levels, chronic kidney disease severity and mineral metabolic disorders associated to chronic kidney disease in dogs.
Materials and Methods
Fifteen control and 75 chronic kidney disease dogs were retrospectively included. Serum fibroblast growth factor‐23 concentration and other phosphate metabolite parameters were compared between controls and each International Renal Interest Society stage. Multiple regression analysis was performed to determine the predictors of fibroblast growth factor‐23.
Results
Serum fibroblast growth factor‐23 concentrations were significantly higher in dogs with IRIS stages 2, 3 and 4 chronic kidney disease than those in dogs in control group and with stage 1 and increased along with the severity of chronic kidney disease. Compared with control dogs, serum intact parathyroid hormone significantly increased from stage 2 and serum phosphorus concentrations increased in dogs with stage 4. In dogs with stage 2, fibroblast growth factor‐23 levels significantly increased in those with hyperphosphatemia compared with those with normophosphatemia. While eight of 26 (30.8%) dogs with stage 2 developed hyperparathyroidism (intact parathyroid hormone>8.5 ng/L), 19 (73.1%) dogs with stage 2 had elevated fibroblast growth factor‐23 levels above the reference range (>528 pg/mL). Log creatinine, log intact parathyroid hormone and log product of total calcium and phosphorus were independent predictors of log fibroblast growth factor‐23.
Clinical Significance
This preliminary study suggests that canine fibroblast growth factor‐23 might be involved in mineral metabolic disorders associated to chronic kidney disease in dogs, and this factor could be potentially used as an early marker for this condition.
Plasma N-terminal pro-atrial natriuretic peptide (NT-proANP) concentration increases with
progression of myxomatous mitral valve disease (MMVD) in dogs. This multicentre,
prospective study compared plasma NT-proANP, N-terminal pro-brain natriuretic peptide
(NT-proBNP), ANP, and cardiac troponin I (cTnI) concentrations in dogs with MMVD for their
characteristics and discriminatory ability to detect cardiac dilatation and congestive
heart failure (CHF). Thirty-six healthy dogs and 69 dogs with MMVD were included. Clinical
variables were obtained via physical examination, thoracic radiography, and
echocardiography. The discriminatory ability of each cardiac biomarker (CB) to determine
the presence or absence of cardiac dilatation (event 1) and CHF (event 2) was evaluated
using the receiver operating characteristic curves. Plasma NT-proANP, NT-proBNP, and ANP
concentrations showed a significant association with the left atrium/aorta ratio
(
P
<0.01). The area under the curve of plasma NT-proANP and NT-proBNP
concentrations were 0.72 and 0.75, respectively in event1 and 0.72 and 0.76, respectively
in event2. Plasma NT-proANP and NT-proBNP concentrations showed sensitivity 80.0 and
80.0%; specificity 67.6 and 64.7% in event1 (cutoff value; 8,497.81 pg/ml and 1,453.00
pmol/l, respectively) and sensitivity 85.7 and 81.0%; specificity 60.4 and 64.6% in event2
(cutoff value; 8,684.33 pg/ml and 1,772.00 pmol/l, respectively). In dogs with MMVD,
plasma NT-proANP, NT-proBNP, and ANP concentrations increase with left atrial enlargement.
Particularly, plasma NT-proANP and NT-proBNP concentrations appeared to be equally useful
in the discriminatory ability to detect cardiac dilatation and CHF.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.